Investment analysts at Stephens initiated coverage on shares of Recro Pharma (NASDAQ:REPH) in a research note issued to investors on Wednesday, The Fly reports. The firm set an “overweight” rating on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on REPH. ValuEngine cut Recro Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. Zacks Investment Research cut Recro Pharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 10th. Oppenheimer set a $20.00 target price on Recro Pharma and gave the company a “buy” rating in a report on Friday, August 9th. Finally, BidaskClub upgraded Recro Pharma from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 8th. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $12.70.

Shares of REPH traded up $0.25 on Wednesday, reaching $11.77. The stock had a trading volume of 130,088 shares, compared to its average volume of 273,053. The firm has a market capitalization of $258.39 million, a PE ratio of -4.73 and a beta of -0.50. The firm has a 50-day moving average of $11.60 and a 200 day moving average of $9.96. Recro Pharma has a twelve month low of $5.53 and a twelve month high of $12.67.

Recro Pharma (NASDAQ:REPH) last released its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.29. The firm had revenue of $31.26 million during the quarter, compared to analyst estimates of $24.06 million. As a group, equities analysts anticipate that Recro Pharma will post -0.48 EPS for the current year.

A number of large investors have recently made changes to their positions in the business. Bowling Portfolio Management LLC acquired a new stake in Recro Pharma during the 3rd quarter valued at $423,000. River & Mercantile Asset Management LLP acquired a new stake in Recro Pharma during the 2nd quarter valued at $2,166,000. Royal Bank of Canada acquired a new stake in Recro Pharma during the 2nd quarter valued at $198,000. Engine Capital Management LP grew its holdings in Recro Pharma by 3.8% during the 2nd quarter. Engine Capital Management LP now owns 1,104,546 shares of the specialty pharmaceutical company’s stock valued at $11,233,000 after buying an additional 40,000 shares during the last quarter. Finally, Voloridge Investment Management LLC acquired a new stake in Recro Pharma during the 2nd quarter valued at $152,000. Hedge funds and other institutional investors own 60.50% of the company’s stock.

About Recro Pharma

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Featured Story: Trading Options- What is a Strangle?

The Fly

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.